Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer
2014 San Antonio Breast Cancer Symposium
Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therapeutics for endocrine therapy-resistant estrogen receptor-positive breast cancer.
Jack Cuzick, PhD
Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Clifford A. Hudis, MD, FACP
Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.